Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT03092674 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

76

Enrollment

NIH

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome/Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
DRUG: Cytarabine
DRUG: Decitabine
OTHER: Laboratory Biomarker Analysis
DRUG: Midostaurin
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)